Paul A. Brennan
Corporate Officer/Principal chez EUPRAXIA PHARMACEUTICALS INC.
Fortune : 88 128 $ au 31/03/2024
Profil
Paul A.
Brennan currently works at Eupraxia Pharmaceuticals, Inc., as Chief Business Officer from 2022.
Mr. Brennan also formerly worked at InMed Pharmaceuticals, Inc., as President, Chief Executive Officer & Director, MIGENIX, Inc., as Chief Executive Officer from 2009 to 2010, Global Gaming Technologies Corp., as Chief Executive Officer in 2010, Altair Therapeutics, Inc., as Chief Executive Officer in 2009, NervGen Pharma Corp., as President, Chief Executive Officer & Director from 2019 to 2022, AstraZeneca PLC, as Director-Global Licensing, Astra Draco AB, as Director-Business Development & Licensing, AnorMED, Inc., as Acting President & VP-Business Development from 2002 to 2006, Aspreva Pharmaceuticals Corp., as Senior Vice President-Business Development in 2008, Arbutus Biopharma Corp., as Senior Vice President-Business Development from 2010 to 2015, Eupraxia Pharmaceuticals, Inc., as Chief Business Officer in 2019, Aquinox Pharmaceuticals, Inc., as Vice President-Business Development from 2016 to 2018, and Pacific Biopartners, as Principal.
Mr. Brennan received his undergraduate degree and graduate degree from Queen's University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 18/08/2023 | 27 200 ( 0,10% ) | 88 128 $ | 31/03/2024 |
Postes actifs de Paul A. Brennan
| Sociétés | Poste | Début |
|---|---|---|
| EUPRAXIA PHARMACEUTICALS INC. | Corporate Officer/Principal | 01/11/2022 |
Anciens postes connus de Paul A. Brennan
| Sociétés | Poste | Fin |
|---|---|---|
| NERVGEN PHARMA CORP. | Chief Executive Officer | 22/09/2022 |
| EUPRAXIA PHARMACEUTICALS INC. | Corporate Officer/Principal | 01/11/2019 |
Aquinox Pharmaceuticals, Inc.
 Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Corporate Officer/Principal | 01/07/2018 |
| ARBUTUS BIOPHARMA CORPORATION | Corporate Officer/Principal | 01/08/2015 |
| GLOBAL GAMING TECHNOLOGIES CORP. | President | 01/09/2010 |
Formation de Paul A. Brennan
| Queen's University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| INMED PHARMACEUTICALS INC. | Health Technology |
| ARBUTUS BIOPHARMA CORPORATION | Health Technology |
| GLOBAL GAMING TECHNOLOGIES CORP. | Finance |
| EUPRAXIA PHARMACEUTICALS INC. | Health Technology |
| NERVGEN PHARMA CORP. | Health Technology |
| Entreprise privées | 7 |
|---|---|
AnorMED, Inc.
 AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | Health Technology |
MIGENIX, Inc.
 MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | Health Technology |
Aspreva Pharmaceuticals Corp.
 Aspreva Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Aspreva Pharmaceuticals Corp. manufactured pharmaceutical products. It offered therapeutic products, research equipment, and related services. The firm developed drugs for the treatment of cancer, infectious diseases, and immune disorders. The company was founded in 2001 and is headquartered in Victoria, Canada. | Health Technology |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
| Astra Draco AB | |
Altair Therapeutics, Inc.
 Altair Therapeutics, Inc. Medical DistributorsDistribution Services Altair is a privately owned company that was spun out of ISIS Pharmaceuticals in October 2007 with the objective of applying ISIS’s proprietary second generation (2’-MOE Gapmer) antisense oligoneucleotide technology to the field of inhaled therapeutics. Through its collaboration with ISIS Altair has access to both near term clinical stage opportunities, as well as early stage development projects. Altair's first compound AIR645 is currently in phase I clinical trials. This first in class compound posses unique anti-inflammatory activities appropriate for multiple therapeutic applications, including asthma, rhinitis and COPD. Additionally, the characteristics of the 2'-MOE Gapmer chemistry provides for the possibility of administration of AIR645 as an inhaled therapeutic delivered once weekly. Altair is also planning on developing a future pipeline of other best-in-class molecules for respiratory targets by exploiting the advantages of its propriety 2nd generation antisense oligonucleotide chemistry. | Distribution Services |
| Pacific Biopartners |
